Prenatal Dex Study
Key facts
- Who runs it
- Hospices Civils de Lyon
- Where
- France10 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 354 people enrolled
- Started
- 4 Oct 2016
- Ended
- 13 Jun 2025
- Type of study
- Interventional, 5 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Neuropsychological and cognitive assessment
- Record updated
- 11 December 2025
Who can take part
- Age
- 6 years to 15 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Groups D+1, D+2, D-1 and D-2
- Male or female
- Patient with Congenital Adrenal Hyperplasia or sibling of a CAH patient
- Age: 6 to 15 years (at the time of inclusion)
- The subject's legal representatives have understood the information note/informed consent form, obtained answers to all their questions and have given signed, written, informed consent
- Subject with health insurance; Group D-3 (Schoolchildren)
- Male or female
- With no connection with Congenital Adrenal Hyperplasia
- Age: 6 to 15 years (at the time of inclusion)
- The subject's legal representatives have understood the information note/informed consent form, obtained answers to all their questions and have given signed, written, informed consent
- Subject with health insurance
Who cannot take part
- Patient/Subject whose mother has received another treatment during her pregnancy with possible known adverse events on the neuropsychological development of the child
- Patient/Subject with another genetic disease
- Patient/Subject with known neuropsychology disease(s)
- For all groups :
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The classic form of 21-hydroxylase deficiency (prevalence 1/15,000) is the most common cause of congenital adrenal hyperplasia (CAH). This autosomic recessive disease is responsible for virilization of the external genitalia in girls through androgen hypersecretion during fetal life. Since 1984, the Lyon Pediatric Endocrinology group has proposed prenatal dexamethasone (DEX) for all fetuses at risk of CAH With the aim of preventing fetal androgen hypersecretion in affected girls and avoiding poor long-term results from reconstructive surgery. Prenatal DEX was used in Europe and the USA but its use was recently suspended: in 2007, a Swedish study conducted on 26 children treated with DEX in utero for a short period of time reported cognitive impairments. These data were not confirmed by an American study on the short-term DEX use, which showed potential cognitive impairments in CAH children exposed to DEX for long periods of time. These confusing and controversial results have caused the scientific community to question its position and have resulted in the suspension of the use of prenatal DEX with drastic consequences for CAH girls (virilization; genital surgery etc.). In this context, an evaluation of neuropsychological development under in utero DEX is essential to validate its indication for use during the prenatal period. This study will evaluate outcomes using prospective cognitive and emotional assessments. It will first focus on the unaffected children previously treated in utero in order to assess the adverse effects of the drug. The study will then assess the children with CAH for whom DEX could have beneficial effects.
The 5 groups in the trial
- Group D+ 1Treatment being tested
Girls and boys at risk of CAH treated in utero by Dexamethasone but unaffected.
Treatment: Neuropsychological and cognitive assessment
- Group D+ 2Treatment being tested
Girls and boys affected by CAH and treated in utero by Dexamethasone.
Treatment: Neuropsychological and cognitive assessment
- : Group D - 1Existing treatment, for comparison
Girls and boys not affected by CAH and not treated in utero by Dexamethasone.
Treatment: Neuropsychological and cognitive assessment
- Group D - 2Existing treatment, for comparison
Girls and boys affected by CAH and not treated in utero by Dexamethasone.
Treatment: Neuropsychological and cognitive assessment
- Group D - 3Other group
Girls and boys enrolled in school closed to Lyon
Treatment: Neuropsychological and cognitive assessment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multicentric Evaluation of in Utero Dexamethasone (DEX) on the Cognitive Development of Children at Risk of Congenital Adrenal Hyperplasia
- Record updated
- 11 December 2025